Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEZOGIST
2022-503068-34-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Imatinib + atezolizumab with Imatinib alone (2 arms). Primary endpoint: Progression-Free Survival. Planned start Jan 2024; status: authorised.
02
Drugs
imatinibatezolizumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2022-503068-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503068-34-00.